US Capitol Capsule: Stem cell researchers breathe sigh of relief on vacated injunction
This article was originally published in Scrip
Researchers last week cheered a 29 April ruling by a US appeals court that vacated an injunction imposed last August by a lower court on federal funding for research involving human embryonic stem cells (hESCs) – with the latest decision giving the Obama administration a big win in the case. The ruling also bodes well for companies involved in hESC research, although the 29 April decision has no impact on the clinical trials underway by the two US firms already given the US FDA's blessing to move forward.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.